SEC filing · 8-K

Avalyn Pharma Inc.: Executive or director change

Avalyn Pharma appointed Dr. Robert Meyer to its board of directors as an independent Class II director.

Filed September 16, 2026

Positive for the company

What happened

On September 15, 2026, the board appointed Robert Meyer, M.D. as a Class II director with a term expiring at the 2028 annual meeting of stockholders.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Avalyn Pharma Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.